KRAS and colorectal carcinoma: In fact, in CRC cell lines, KRAS G12C inhibition was shown to induce greater EGFR-mediated, MAPK pathway reactivation, thus supporting EGFR as a valuable target to overcoming resistance to KRAS covalent inhibitors in mCRC.